Druggist

NOVEMBER 6, 2020

Diphenhydramine is a first-generation antihistamine, which is used to in the symptomatic treatment of allergies but more commonly as over the counter temporary sleeping aid medicines. Different brands of cough syrups contain very often the same active ingredients. Diphenhydramine is commonly used in combination with other components.

Medicine 69

Medicine Containment Production Pharmacy 69

Druggist

DECEMBER 9, 2020

Lotions: contain the least amount of oils and higher amounts of water with non-greasy consistency. Clobetasone has a narrow licensed use. It contains a combination of miconazole (an antifungal drug) and hydrocortisone 1% (steroid). Creams: optimal amount of oil vs water, but in higher oil amounts than lotions. Chickenpox.

Pharmacy 97

Pharmacy Containment Sales Production 97

The Pharma Data

JANUARY 12, 2021

Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

DECEMBER 8, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S.

Vaccination 40

Vaccination Vaccine Manufacturing Containment 40

The Pharma Data

JANUARY 24, 2021

It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes.

Trials 52

Trials Allergies In-Vitro Antibody 52

Pfizer

JANUARY 27, 2023

In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. Most of this work is conducted using computer simulations or mutations of the main protease–a non-infectious part of the virus.

Research 112

Research Vaccination Vaccine Drugs 112

Pfizer

DECEMBER 8, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron sublineages BA.4/BA.5, Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. INDICATION.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Pfizer

NOVEMBER 2, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron BA.4/BA.5 Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. INDICATION.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

AUGUST 17, 2021

Lyumjev U-200 contains 2 times as much insulin in 1 milliliter as Lyumjev U-100. Humalog U-100 contains 100 units of insulin per milliliter. All Lyumjev and Humalog products contain insulin lispro. drink alcohol or use other medicines that contain alcohol when taking your Lyumjev or Humalog. Learn more.

Insulin 52

Insulin FDA Approval Doctor Doctors 52

The Pharma Data

MAY 4, 2021

About OLUMIANT ® (baricitinib) OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology , Chinese Academy of Science (IMCAS). It is approved in the U.S.

Antibody 52

Antibody Medicine FDA Approval Licensing 52

Pfizer

JULY 26, 2022

Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID 19) in individuals 6 months of age and older. The information contained in this release is as of July 27, 2022. Emergency Use Authorization .

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Pfizer

SEPTEMBER 28, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus . The information contained in this release is as of September 28, 2022. . • receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. .

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

Pfizer

JULY 8, 2022

Food and Drug Administration (FDA) approved the companies’ supplemental Biologics License Application (sBLA) for their COVID-19 vaccine, known as COMIRNATY® (COVID-19 Vaccine, mRNA), to include individuals 12 through 15 years of age. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

Druggist

OCTOBER 17, 2020

Lovima – ‘mini pill’ available over the counter Lovima contraceptive pill contains 75mcg or desogestrel, which is a synthetic version of the hormone progesterone. Licensing detail for the supply of Lovima over the counter are not known yet. Customers will need to pay for Lovima when supply is made from the pharmacy.

Pharmacy 94

Pharmacy Doctor Doctors Containment 94

The Pharma Data

DECEMBER 23, 2020

CONTACTS: Media: Jeff Richardson , 267-440-4211, jrichardson@inovio.com Investors: Ben Matone , 484-362-0076, ben.matone@inovio.com.

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

NOVEMBER 9, 2020

Bamlanivimab remains an investigational drug and has not been approved under a Biologics License Application (BLA). Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center.

Antibody 52

Antibody Medicine Manufacturing Trials 52

The Pharma Data

APRIL 27, 2021

to €283 million, reflecting growth of Digestive and Mental Wellness categories as well as Allergy partially offset by the decline of the Pain category. Development for Dupixent ® for grass allergy has been discontinued. At CER, BOI increased 48.6%. The ratio of BOI to net sales was 40.5% (and 27.5% Consumer Healthcare. Change at CER.

Sales 52

Sales Vaccination Vaccine Medicine 52

Pfizer

JULY 19, 2022

Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID 19) in individuals 6 months of age and older. The information contained in this release is as of July 19, 2022. Emergency Use Authorization.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

The Pharma Data

JANUARY 26, 2021

Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19. .

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52

Pfizer

SEPTEMBER 16, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus . COMIRNATY® (COVID-19 Vaccine, mRNA) INDICATION. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. EMERGENCY USE AUTHORIZATION.

Marketing 75

Marketing Vaccination Vaccine Clinical Trials 75

Pfizer

JULY 8, 2022

Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID 19) in individuals 6 months of age and older. The information contained in this release is as of July 8, 2022. Emergency Use Authorization.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Pfizer

OCTOBER 19, 2022

Monovalent refers to any authorized and approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2 virus. Tell your vaccination provider about all of your medical conditions, including if you: have any allergies. The information contained in this release is as of October 19, 2022.

Vaccination 40

Vaccination Vaccine Clinical Trials Clinical Trials 40

XTalks

AUGUST 2, 2023

It contains the antiviral medications nirmatrelvir and ritonavir. Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. billion in 2022.

Sales 85

Sales Manufacturing FDA Approval Life Science 85

The Pharma Data

NOVEMBER 9, 2020

Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. 10 World Allergy Organization (WAO). 11 Busse WW.

Trials 52

Trials Production Sales Manufacturing 52

The Pharma Data

NOVEMBER 30, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. W911QY-20-C-0100.

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52

The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. in the Allergy & Cold category. EBITDA before special items at Crop Science decreased by 6.2 This led to a decline of 30.1

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

JANUARY 4, 2021

The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center. To learn more, visit www.modernatx.com. Forward Looking Statements.

Vaccination 52

Vaccination Vaccine Medicine Containment 52

The Pharma Data

DECEMBER 21, 2020

Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. J Allergy Clin Immunol. 2019;74 (2): 273-283.

Trials 40

Trials Production Sales Manufacturing 40

The Pharma Data

FEBRUARY 8, 2021

In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. Allergy Cough & Cold. to €238 million, reflecting growth in the Allergy (Allegra ® and Xyzal ® ) and Digestives categories. at CER) to €2,276 million. Consumer Healthcare.

Sales 52

Sales Vaccine Vaccination Production 52

The Pharma Data

FEBRUARY 4, 2021

In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. Allergy Cough & Cold. to €238 million, reflecting growth in the Allergy (Allegra ® and Xyzal ® ) and Digestives categories. at CER) to €2,276 million. Consumer Healthcare.

Sales 52

Sales Vaccine Vaccination Production 52

The Pharma Data

NOVEMBER 4, 2020

In addition, Amarin recognized licensing and royalty revenue of approximately $1.3 This compares with licensing and royalty revenue of $0.2 It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Licensing and royalty revenue.

Sales 40

Sales Production Marketing Cardiology 40

The Pharma Data

DECEMBER 23, 2020

This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.” Govindarajan, Managing Director, Aurobindo Pharma Limited , said: “We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the COVID-19 pandemic. ” .

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

The Pharma Data

DECEMBER 23, 2020

Under the signed license agreement, Aurobindo Pharma has obtained the exclusive rights to commercialize in India and to UNICEF and non-exclusive rights in other select emerging and developing markets. This vaccine has immense potential in eliminating shedding and hence containing the spread of the pandemic.”.

Vaccination 52

Vaccination Vaccine Manufacturing Antibody 52